Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

What Was Tested

Researchers studied Insulin Glargine and Liraglutide in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The primary end point was change from baseline to week 8 in incremental area under the postprandial plasma glucose curve for 4 h after a standardized solid breakfast (AUC PPG0030-0430 h).

How the Study Was Run

The design is described as randomized, double-blind, open-label and multicenter.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Glargine.

Nothing was hidden in this open-label Insulin Glargine study: the participants and staff both knew the treatment.

Running at several centres spread the Insulin Glargine study over different clinics and patient groups.

Changes from baseline in gastric emptying, 24-h plasma glucose profile, HbA1c, fasting plasma glucose (FPG), 24-h ambulatory heart rate and blood pressure, amylase and lipase levels, and adverse events (AEs) were also assessed.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Gastric Emptying, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin Glargine.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Insulin Glargine and Liraglutide.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page and the Liraglutide compound page.